Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DOXYCYCLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DOXYCYCLINE.
AUREOMYCIN vs DOXYCYCLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Clinical Note
moderateMethoxsalen + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Doxycycline
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic
"The metabolism of Doxycycline can be decreased when combined with Docetaxel."